In an interview with PharmaShots, Rami Levin, Chief Executive Officer at Saniona shared his views on the US FDA's Orphan Drug Designation (ODD) to Tesomet for the treatment of hypothalamic obesity (HO) and discuss its role in the company's continued pipeline progress.Shots:Saniona reported that the FDA has granted orphan drug designation to Tesomet for the…
